Replies to post #244626 on NorthWest Biotherapeutics Inc (NWBO)

[sentiment_stocks]

hmmm... well LL once said that the data from their UCLA trials showed that IDH1 wild-type do best on DCVax-L.

48:10

But some of our data from our immunotherapy trials (note: plural) though, actually have shown immune therapy actually may be more beneficial in the, you know, mesenchymal subgroup of glioblastomas, which actually tend to be IDH1 mutation negative… the IDH1 wild-type tumors. And potentially, these tumors do worse because they have more mutations, and they tend to be more aggressive. That being said, the fact that they have more mutations may actually make them more susceptible to immunotherapy because they have more targets. You know, there are mutations that the immune system can target.

So fingers crossed.